Genetic susceptibility for breast cancer - Risk assessment and counseling

Seminars in Oncology

Volumn 28, Issue 4, 2001, Pages 419-433

  Ang, Peter ^a,b   Garber, Judy E ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; GENETIC SUSCEPTIBILITY; HERITABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0034889354     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90134-4     Document Type: Article

References (130)

1. Cancer statistics, 2000
2. The hormonal basis of breast cancer
3. Endogenous sex hormone levels and breast cancer risk
4. Combined effect of childbearing, menstrual events, and body size on age- specific breast cancer risk
5. Menopause and breast cancer risk
6. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
7. Breast-cancer risk following long-term oestrogen- and oestrogen- progestin-replacement therapy
8. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
9. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
10. Breast cancer risk and alcohol consumption: Results from a large case-control study
11. Dual effects of weight and weight gain on breast cancer risk
12. Second cancers following pediatric Hodgkin's disease
13. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987
14. Risk factors for breast cancer in Chinese women in Shanghai
15. Lactation history and breast cancer risk
16. Physical exercise and reduced risk of breast cancer in young women
17. Breast cancer: Weighing the evidence for a promoting role of dietary fat
18. Association of dietary intake of fat and fatty acids with risk of breast cancer
19. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
20. Validation of a breast cancer risk assessment model in women with a positive family history
21. Validation of the Gail et al. model for predicting individual breast cancer risk
22. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
23. Validation studies for models projecting the risk of invasive and total breast cancer incidence
24. Genetic counseling for BRCA1/BRCA2 testing
25. Accuracy of family history of cancer: Clinical genetic implications
26. Intraductal component and BRCA1-associated breast cancer
27. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
28. In-situ breast cancer and BRCA1
29. Family history, age, and risk of breast cancer. Prospective data from the nurses' health study
30. Genetic analysis of breast cancer in the cancer and steroid hormone study
31. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer
32. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
33. Perception of breast cancer risk among women in breast center and primary care settings: Correlation with age and family history of breast cancer
34. The genetic attributable risk of breast and ovarian cancer
35. Mutation and cancer: Statistical study of retinoblastoma
36. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
37. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours
38. A cancer family syndrome in twenty-four kindreds
39. Will the real Cowden syndrome please stand up: Revised diagnostic criteria
40. Inherited genetic predisposition in breast cancer. A population-based perspective
41. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility
42. Linkage of early-onset familial breast cancer to chromosome 17q21
43. A prospective study of the effect of alcohol consumption and ADH3 genotype on plasma steroid hormone levels and breast cancer risk
44. Polymorphic repeat in AIB1 does not alter breast cancer risk
45. N-acetyl transferase 2 genotypes, meat intake and breast cancer risk
46. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
47. Identification of the breast cancer susceptibility gene BRCA2
48. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1
49. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
50. BRCA1 mutations in primary breast and ovarian carcinomas
51. Frequency of germline and somatic BRCA1 mutations in ovarian cancer
52. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer
53. BRCA2 mutations in primary breast and ovarian cancers
54. In search of the tumour-suppressor functions of BRCA1 and BRCA2
55. Roles of BRCA1 and its interacting proteins
56. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
57. BRCA1 mutations in a population-based sample of young women with breast cancer
58. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
59. Study of a single BRCA2 mutation with high carrier frequency in a small population
60. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young, breast carcinoma cases
61. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early- onset breast cancer
62. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population based case-control studies of ovarian cancer
63. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2
64. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
65. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
66. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
67. Germline BRCA1 mutations in Jewish and non-Jewish women with early- onset breast cancer
68. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
69. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
70. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families
71. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
72. Risks of cancer in BRCAl-mutation carriers
73. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
74. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
75. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation
76. Cancer risks in BRCA2 mutation carriers
77. DNA sequencing with chain-terminating inhibitors
78. Conversion of diploidy to haploidy
79. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, adopted on February 20, 1996
80. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
81. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
82. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
83. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene
84. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent
85. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes
86. What you don't know can hurt you: Adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing
87. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2
88. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
89. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations
90. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families
91. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry
92. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
93. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
94. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
95. Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee
96. The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study
97. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
98. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
99. BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
100. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
101. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
102. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use
103. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women
104. Oral contraceptives and the risk of hereditary ovarian cancer
105. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
106. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers
107. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
108. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
109. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
110. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations
111. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs
112. Genetic discrimination: Perspectives of consumers
113. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination
114. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
115. Localization of the gene for Cowden disease to chromosome 10q22-23
116. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
117. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations
118. The genetic basis of Muir-Torre syndrome includes the hMLH1 locus
119. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face
120. Multiple sebaceous tumors
121. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG, HNPCC) criteria and results of genetic diagnosis
122. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase
123. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
124. Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 27-year follow-up
125. Very high risk of cancer in familial Peutz-Jeghers syndrome
126. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
127. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia
128. Breast and other cancers in families with ataxia-telangiectasia